Hangzhou Highlightll Pharmaceutical Co., Ltd.

杭州高光制药股份有限公司

Clinical-stage biotechnology company developing small-molecule therapeutics for autoimmune/inflammatory and neurodegenerative diseases, including TYK2/JAK1 inhibitors with Phase III trials in China for chronic spontaneous urticaria and rheumatoid arthritis.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Losses and path to profitability
• Net current liabilities or net liabilities
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Non-IFRS measures and adjustments
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech
• Sanctioned countries and export controls